102245-65-8

Basic information

• Product Name: 4-(TERT-BUTYL-DIMETHYL-SILANYLOXY)-BUT-2-YNOIC ACID
• Synonyms: 4-(TERT-BUTYL-DIMETHYL-SILANYLOXY)-BUT-2-YNOIC ACID;4-(TERT-BUTYLDIMETHYLSILYLOXY)-2-BUTYNOIC ACID;4-(Tert-Butyldimethylsilanyloxy)but-2-ylnoicacid;4-(tert-butyldimethylsilyloxy)but-2-ynoic acid
• CAS NO: 102245-65-8
• Molecular Formula: C₁₀H₁₈O₃Si
• Molecular Weight: 214.33
• Mol File: 102245-65-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 268.1±23.0 °C(Predicted)
• Appearance: /
• Density: 1.003±0.06 g/cm3(Predicted)
• PKA: 2.04±0.10(Predicted)
• CAS DataBase Reference: 4-(TERT-BUTYL-DIMETHYL-SILANYLOXY)-BUT-2-YNOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(TERT-BUTYL-DIMETHYL-SILANYLOXY)-BUT-2-YNOIC ACID(102245-65-8)
• EPA Substance Registry System: 4-(TERT-BUTYL-DIMETHYL-SILANYLOXY)-BUT-2-YNOIC ACID(102245-65-8)

Safety Data

• Hazardous Substances Data: 102245-65-8(Hazardous Substances Data)

Usage

General Description

4-(tert-butyl-dimethyl-silanyloxy)-but-2-ynoic acid is a chemical compound that belongs to the class of alkynes, which are organic compounds containing a triple bond between two carbon atoms. 4-(TERT-BUTYL-DIMETHYL-SILANYLOXY)-BUT-2-YNOIC ACID has a tert-butyl group and a dimethyl-silanyloxy group attached to the carbon chain, giving it unique properties and potential applications in organic synthesis and materials science. The presence of the triple bond makes it a versatile building block for the preparation of various functionalized organic compounds. Additionally, the silanyloxy group enhances the stability and reactivity of the compound, making it useful in chemical reactions and as a precursor for the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals. Overall, 4-(tert-butyl-dimethyl-silanyloxy)-but-2-ynoic acid is a valuable compound with potential uses in the field of organic chemistry and materials research.

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 124-38-9 carbon dioxide 
• 76782-82-6 tert-Butyldimethyl(prop-2-ynyloxy)silane 

Downstream Products

• 214486-65-4 N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinolinyl]-4-(tert-butyl-dimethyl-silanyloxy)-2-butynamide 

Relevant articles and documents

SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS

This invention provides compounds of formula (1) wherein X is C3-7 cycloalkyl, pyridinyl, pyrimidinyl or phenyl ring optionally substituted as described in claim 1, R1, R3 and R4 are chosen from the groups listed in claim 1. R2 is chosen from various unsaturated acyl groups listed in claim 1, with certain compounds being disclaimed. Use as tyrosine kinase inhibitors for the treatment of cancer and certain kidney diseases such as polycystic kidney disease.

6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity

A series of new 6-substituted-4-(3-bromophenylamino)quinazoline derivatives that may function as irreversible inhibitors of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases have been prepared. These inhibitors have, at the C-6 position, butynamide, crotonamide, and methacrylamide Michael acceptors bearing water-solublilizing substituents. These compounds were prepared by acylation of 6-amino-4-(3-bromophenylamino)quinazoline with unsaturated acid chlorides or mixed anhydrides. We show that attaching a basic functional group onto the Michael acceptor results in greater reactivity, due to intramolecular catalysis of the Michael addition and/or an inductive effect of the protonated basic group. This, along with improved water solubility, results in compounds with enhanced biological properties. We present molecular modeling and experimental evidence that these inhibitors interact covalently with the target enzymes. One compound, 16a, was shown to have excellent oral activity in a human epidermoid carcinoma (A431) xenograft model in nude mice.

3-(Optionally substituted-but-1-en-3-ynyl) cephalosporins

Compounds of general formula I STR1 (wherein R represents NH2 -- or an acylated or silylated amino group; R2 represents a hydrogen, halogen, alkyl, aryl, carboxyl or lower alkoxycarbonyl group; R3 is hydrogen or a carboxyl blocking group; B is >Sor>S→O (α- or β-); and the dotted line represents Δ2 or Δ3 unsaturation) and salts, solvates and esters thereof are described. Compounds where R3 is hydrogen, the dotted line represents Δ3 unsaturation and R is a group of formula STR2 (where Ra is an optionally substituted heterocyclic aryl group having one or more hetero atoms selected from S, N and O in the ring, Rb is an optionally substituted aryl group, Rc is hydrogen, acyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl, Rd is as defined for Ra or is an optionally substituted group and X is amino, hydroxyl, acylated hydroxyl, carboxyl or esterified carboxyl) and especially the compounds in which B is >S, have valuable antibiotic activities. Compounds in which the --CH=CH--C C--R2 group is in the trans configuration have been found to have good oral absorption. The remaining compounds of formula (I) are valuable as intermediates in processes for the preparation of the above active antibiotics, which processes are also described.